$RGNX News

REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results

B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14

Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12

REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript

REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

Regenxbio's Shares Topline And Interim Functional Data From Pivotal Phase 3 Portion Of Phase 1/2/3 Affinity Duchenne Trial Of RGX-202 For Duchenne Muscular Dystrophy, Meeting The Primary Endpoint With High Statistical Significance

Regenxbio Enters Settlement And Release Agreement With GlaxoSmithKline On March 18, 2026; To Pay $10.0M To GlaxoSmithKline For Alleged Underpayment Of Sublicense Fees; Settlement Agreement Includes Mutual Releases Of Past And Certain Future Claims; To Continue To Pay GSK Amounts Received From Sublicensees Pursuant To Existing Sublicense Agreements

REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

REGENXBIO's RGX-202 Reports 1-Year Results In Duchenne Muscular Dystrophy, With Pivotal Dose Patients Exceeding External Controls On Functional Measures, Cardiac MRI Stability And Liver Safety; Phase I/II AFFINITY Trial Topline Data Expected Q2 2026

HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $30

The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts

Morgan Stanley Maintains Overweight on Regenxbio, Lowers Price Target to $17

Assessing Where Regenxbio Stands After FY25 Results

REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript

REGENXBIO INC (NASDAQ:RGNX) Stock Plunges 15% After Q4 Earnings Miss

Regenxbio Earnings Report: Q4 Overview

Regenxbio Q4 EPS $(1.30) Misses $(0.58) Estimate, Sales $30.337M Miss $36.561M Estimate.